Your browser doesn't support javascript.
loading
2021 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk / 임상당뇨병
Journal of Korean Diabetes ; : 259-267, 2021.
Artigo em Coreano | WPRIM | ID: wpr-918901
ABSTRACT
The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 7th Clinical Practice Guidelines in 2021. Intense multifactorial intervention including adequate control of glycemia, blood pressure, and low density lipoprotein cholesterol level and use of antiplatelet agents has been shown to reduce cardiovascular risk among patients with type 2 diabetes mellitus. In these recent guidelines, sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with proven benefits were recommended in patients with heart failure and/or atherosclerotic cardiovascular disease (ASCVD) as mono- or combination therapy. SGLT2 inhibitors such as dapagliflozin, empagliflozin, and ertugliflozin were recommended preferentially in patients with heart failure. In those with ASCVD, treatment including SGLT2 inhibitors such as empagliflozin and dapagliflozin or GLP-1 RAs such as dulaglutide, liraglutide, and semaglutide as a combination therapy was recommended.
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Estudo de etiologia / Guia de Prática Clínica Idioma: Coreano Revista: Journal of Korean Diabetes Ano de publicação: 2021 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Estudo de etiologia / Guia de Prática Clínica Idioma: Coreano Revista: Journal of Korean Diabetes Ano de publicação: 2021 Tipo de documento: Artigo